16 July 2023 : Clinical Research
A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy
Hanzhao Yang1CDE, Yadong Sun1BCD, Peili Wang1BD, Jianghua Qiao1BC, Lianfang Li1B, Zhenduo Lu1B, Xianfu Sun1B, Chongjian Zhang1B, Xiuchun Chen1B, Min Yan1B, Shude Cui1B, Chengzheng Wang1ADF, Zhenzhen Liu1AEDOI: 10.12659/MSM.940124
Med Sci Monit 2023; 29:e940124
Table 1 Characteristics of HR+/HER2− patients.
| Characteristics | Patients (n=444) |
|---|---|
| Age, Median (min, max), years | 50 (26–80) |
| <50, no. (%) | 215 (48.4%) |
| ≥50, no. (%) | 229 (51.6%) |
| BMI | 24.4 (22.3–26.1) |
| Menopausal status, no. (%) | |
| Premenopausal | 254 (57.2%) |
| Postmenopausal | 190 (42.8%) |
| Multifocality, no. (%) | |
| Absent | 394 (88.7%) |
| Present | 50 (11.3%) |
| Clinical tumor stage, no. (%) | |
| 1 | 274 (61.7%) |
| 2 | 170 (38.3%) |
| Tumor size, Median (min, max), cm | 1.9 (0.2–5.0) |
| US-ALN, no. (%) | |
| Normal | 298 (67.1%) |
| Abnormal | 146 (32.9%) |
| Mammographic calcifications, no. (%) | |
| Absent | 365 (82.2%) |
| Present | 79 (17.8%) |
| Surgery, no. (%) | |
| Mastectomy | 350 (78.8%) |
| Breast-conserving | 94 (21.2%) |
| Tumor type, no. (%) | |
| Ductal | 425 (95.7%) |
| Lobular | 15 (3.4%) |
| Others | 4 (0.9%) |
| Histological grade, no. (%) | |
| I | 7 (1.6%) |
| II | 397 (89.4%) |
| Missing | 40 (9.0%) |
| 1 positive SLNs removed. total, no. (%) | 318 (71.6%) |
| 0 positive non-SLNs, no | 166 |
| 1 positive non-SLNs, no | 95 |
| 2 positive non-SLNs, no | 27 |
| ≥3 positive non-SLNs, no | 30 |
| 2 positive SLNs removed. total, no. (%) | 126 (28.4%) |
| 0 positive non-SLNs, no | 62 |
| 1 positive non-SLNs, no | 18 |
| 2 positive non-SLNs, no | 22 |
| ≥3 positive non-SLNs, no | 24 |
| pN stage, no. (%) | |
| 1 | 367 (82.7%) |
| 2–3 | 77 (17.3%) |
| LVI, no. (%) | |
| Absent | 348 (78.4%) |
| Present | 96 (21.6%) |
| Progesterone receptor, no. (%) | |
| Negative | 33 (7.4%) |
| Positive | 411 (92.6%) |
| HER2 expression, no. (%) | |
| 0 | 64 (14.4%) |
| 1+ | 137 (30.9%) |
| 2+ | 243 (54.7%) |
| BMI – body mass index; US-ALN – ultrasound finding axillary lymph node; SLN – sentinel lymph node; LVI – lymphovascular invasion. | |